Sandoz’ biosimilar etanercept candidate shows pharmacokinetic (PK) bioequivalence with no clinically meaningful differences in safety, tolerability and immunogenicity to the originator.1Sandoz’ biosimilar rituximab candidate shows PK bioequivalence and…
Sandoz advances biosimilar portfolio with sixth major biosimilar file acceptance in less than one yearSandoz is seeking approval for all indications included in the reference product’s labelSandoz’ submission includes data from multiple clinical trials…
Holzkirchen, May 23, 2016 – In the wake of the earthquake that devastated northwest Ecuador in April, Sandoz, a Novartis division, today announced that it will support the recovery effort with financial aid and a product donation.Hundreds of people los…
Holzkirchen, 29 April, 2016 – Sandoz’s Carol Lynch, Global Head Biopharmaceuticals, has been named as one of the most influential people involved in bringing medicines to patients by Medicine Maker – a leading international publication focused on drug …
Holzkirchen, 29 April, 2016 – Sandoz’s Carol Lynch, Global Head Biopharmaceuticals, has been named as one of the most influential people involved in bringing medicines to patients by Medicine Maker – a leading international publication focused on drug …
Net sales up 1% (cc[1]), as Growth Products offset Gleevec impactGrowth Products[2] grew 24% (USD) to USD 3.9 billion, or 34% of Group net salesCosentyx (USD 176 million) continues to grow strongly, benefitting from long-term efficacy data for psoriasi…
Net sales up 1% (cc[1]), as Growth Products offset Gleevec impactGrowth Products[2] grew 24% (USD) to USD 3.9 billion, or 34% of Group net salesCosentyx (USD 176 million) continues to grow strongly, benefitting from long-term efficacy data for psoriasi…
Sandoz’ epoetin alfa product offering has already generated more than 400,0001 patient years of experience worldwideEC approval expands Sandoz biosimilar offering to the healthcare communityHolzkirchen, 08 April, 2016 – Sandoz, a Novartis division and …
Sandoz’ epoetin alfa product offering has already generated more than 400,0001 patient years of experience worldwideEC approval expands Sandoz biosimilar offering to the healthcare communityHolzkirchen, 08 April, 2016 – Sandoz, a Novartis division and …
Updated segment financials reflect transfer of Ophthalmic Pharmaceuticals franchise from Alcon to Pharmaceuticals, and 19 mature products from Pharmaceuticals to Sandoz, as outlined in Q4 and FY 2015 earnings releaseNo change in audited 2015 Consolidat…